Morphosys (MOR) has released an update.
MorphoSys AG has announced receiving U.S. antitrust clearance for its acquisition by Novartis AG, satisfying all mandatory regulatory approvals. Novartis plans to launch a voluntary public takeover offer for all MorphoSys shares at €68.00 per share, aiming for a minimum acceptance threshold of 65%. The transaction, valued at €2.7 billion, is anticipated to close in the first half of 2024, subject to customary closing conditions.
For further insights into MOR stock, check out TipRanks’ Stock Analysis page.
